Safety and Efficacy of Transition From Subcutaneous Treprostinil to Oral Sildenafil in Patients With Pulmonary Arterial Hypertension

The transition from subcutaneous treprostinil to sildenafil was safely achieved in most (71%), but not all, patients with pulmonary arterial hypertension of varied etiology. These patients had an improvement in both NYHA functional class and QOL, and maintained stable walk distances over a 3-month period on sildenafil therapy.